MediWound Ltd. (MDWD)
NASDAQ: MDWD · Real-Time Price · USD
13.51
-0.01 (-0.07%)
At close: Oct 5, 2026, 4:00 PM EDT
13.51
0.00 (0.00%)
Pre-market: Oct 6, 2026, 4:00 AM EDT
MediWound Revenue
MediWound had revenue of $3.09M in the quarter ending June 30, 2026, a decrease of -45.83%. This brings the company's revenue in the last twelve months to $11.86M, down -40.26% year-over-year. In the year 2025, MediWound had annual revenue of $16.96M, down -16.14%.
Revenue (ttm)
$11.86M
Revenue Growth
-40.26%
P/S Ratio
14.70
Revenue / Employee
$98,041
Employees
121
Market Cap
174.42M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 16.96M | -3.26M | -16.14% |
| Dec 31, 2024 | 20.22M | 1.54M | 8.22% |
| Dec 31, 2023 | 18.69M | -7.81M | -29.48% |
| Dec 31, 2022 | 26.50M | 2.73M | 11.50% |
| Dec 31, 2021 | 23.76M | 2.00M | 9.19% |
| Dec 31, 2020 | 21.76M | -10.03M | -31.54% |
| Dec 31, 2019 | 31.79M | 28.39M | 834.70% |
| Dec 31, 2018 | 3.40M | 905.00K | 36.26% |
| Dec 31, 2017 | 2.50M | 938.00K | 60.21% |
| Dec 31, 2016 | 1.56M | 957.00K | 159.23% |
| Dec 31, 2015 | 601.00K | 342.00K | 132.05% |
| Dec 31, 2014 | 259.00K | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Coherus Oncology | 50.94M |
| Precision BioSciences | 45.06M |
| Cue Biopharma | 37.66M |
| Oramed Pharmaceuticals | 2.00M |
| Veraxa Biotech AG | 29.54K |
MDWD News
- 14 days ago - MediWound awarded additional $3.3M from DOW to advance NexoBrid - TheFly
- 14 days ago - MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid® - GlobeNewsWire
- 19 days ago - MediWound price target raised to $27 from $22 at Alliance Global - TheFly
- 19 days ago - MediWound says DSMB recommends Phase 3 VALUE study continue without modification - TheFly
- 21 days ago - MediWound Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 22 days ago - Independent DSMB Recommends MediWound's EscharEx® Phase III VALUE Study Continue Without Modification - GlobeNewsWire
- 4 weeks ago - MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire
- 7 weeks ago - MediWound reports Q2 EPS ($1.36), consensus (77c) - TheFly